

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
北京同仁堂國藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3613)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO OF STRATEGIC COOPERATION AGREEMENT

This announcement is made by the Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development about the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company has entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with China Duty Free International Limited (“**CDF International**”).

I. KEY TERMS OF THE STRATEGIC COOPERATION AGREEMENT

(1) Collaboration Objectives

The Company and CDF International regard each other as key cooperative partners and will fully leverage their respective strengths to achieve mutual development and maximize benefits through the collaboration under the Strategic Cooperation Agreement. Both parties will establish a cooperation mechanism to integrate resources and foster mutual success. Both parties will endeavor to deploy the most competitive resources into the collaboration, jointly committing to expanding the Company’s overseas markets, with a focus on countries along the “Belt and Road” and Southeast Asia regions.

(2) Collaboration Contents

1. On the basis of the existing cooperation channels of Hainan duty free stores, membership club and downtown duty free stores in Hong Kong, further expand the scope of cooperation in domestic and overseas channels and products.
2. Both parties will jointly explore the cooperation on exclusive versions of products such as Tong Ren Tang Wood Lok Medicated Oil (同仁堂活絡油) and Chinese Anti-Aging Series for cdf channels.
3. Both parties will jointly explore the cooperation in innovative business models of Chinese health food and beverage, and, in line with the cooperation intention of both parties, promote cooperation of domestic and overseas outlets in a timely manner.
4. Both parties will leverage their respective strengths and explore multi-dimensional cooperation in business, products and culture with the theme of China-Chic brands going overseas.

(3) Collaboration Mechanisms

1. Mutual visits among senior levels. Both parties shall establish a mechanism for regular meetings between senior leaders and a mechanism for routine communication and coordination to address major issues in the course of cooperation and to promote the implementation and deepening of the Strategic Cooperation Agreement.
2. Business cooperation. Both parties will designate relevant leaders and subordinate companies to undertake daily liaison work, be responsible for strengthening consultation and convergence to establish a regular negotiation mechanism. Without violating relevant confidentiality regulations, both parties will enhance information and achievement sharing, unify action strategies, and promote the in-depth development of cooperation.

(4) Effective term

1. The Strategic Cooperation Agreement shall take effect from the date of signing or seal by both parties and shall be valid for two years. The parties shall sign a formal written agreement to confirm the cooperation intention stipulated in the Strategic Cooperation Agreement and if the written cooperation agreement is not signed and confirmed upon expiration of the term, the Strategic Cooperation Agreement shall be terminated and the parties shall not be liable to each other.

II. REASONS AND BENEFITS OF ENTERING INTO OF THE STRATEGIC COOPERATION AGREEMENT

The entering into of the Strategic Cooperation Agreement lays the foundation for the formal co-operation between the parties, which, if successfully concluded, will be conducive to giving full play to the advantages of the parties' respective fields, leveraging the sharing, synergy, integration and complementation of the advantageous resources of both the Company and CDF International. With traditional Chinese medicine culture as a driving force, it will promote the global spread of China-Chic consumer goods. Under the new development framework of prioritizing the domestic cycle and fostering mutual reinforcement between domestic and international dual cycle, both parties will jointly commit to further focusing on the value of traditional Chinese medicine, thereby providing diversified health solutions to people worldwide, and collaboratively shaping the future of the marco-health industry.

III. INFORMATION OF CDF INTERNATIONAL

CDF International is incorporated in Hong Kong, China with limited liability on 21 November 1996. It is wholly owned by China Duty Free Group (Hainan) Operation Headquarter Co., Ltd., a wholly-owned subsidiary of China Tourism Group China Duty Free Corporation Limited, and is mainly engaged in the wholesale and retail business of duty-free goods. CDF International and its ultimate beneficial owner are third parties independent to the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**")).

Shareholders and investors should note that the Strategic Cooperation Agreement is a strategic cooperation intention agreement entered into by both parties. Specific cooperation matters are subject to the definitive agreements to be entered into by the relevant parties. There is still uncertainty in the specific implementation content and progress. If any definitive agreement is entered into, the Company will make a separate announcement in accordance with the Listing Rules as necessary or appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Gu Hai Ou
Chairman

Hong Kong, 8 April 2025

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:

Mr. Gu Hai Ou (*Chairman*)
Mr. Wang Chi
Mr. Chen Fei

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper
Mr. Xu Hong Xi
Mr. Chan Ngai Chi

Non-executive Director:

Ms. Feng Li